Kenneth Lebioda, Senior Vice President of Business & Corporate Development of Resverlogix stated, "The inflammation market is enormous with many significant unmet needs. Current leading therapeutics such as biologics are effective, but also very expensive. Resverlogix's platform technology has created novel small molecules which illustrate potent anti-inflammatory effects in arthritis models as compared with leading biologic agents." Lebioda highlighted, "The early efficacy data from these compounds is exciting for the reason that small molecules would offer significant cost savings to health systems over current biologic agents."
Inflammation is a normal response of the body to protect tissues from infection, injury or disease. Though it promotes healing, if uncontrolled, the inflammatory response may become harmful. Acute or chronic inflammation is known to play a key role in diverse disease states, such as atherosclerosis and rheumatoid arthritis. Worldwide it is estimated that more than 80 million people suffer from inflammatory diseases.
Resverlogix will be presenting at the BIO Business Forum held at the Convention Center in Atlanta, Georgia on Wednesday, May 20, 2009 at 9:20 am EDT in Room 313.
About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas(TM) PR program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's disease
|SOURCE Resverlogix Corp.|
Copyright©2009 PR Newswire.
All rights reserved